631 related articles for article (PubMed ID: 33028804)
1. Advances in targeted therapy for esophageal cancer.
Yang YM; Hong P; Xu WW; He QY; Li B
Signal Transduct Target Ther; 2020 Oct; 5(1):229. PubMed ID: 33028804
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S; Kato K
Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Esophageal carcinoma: Towards targeted therapies.
Fatehi Hassanabad A; Chehade R; Breadner D; Raphael J
Cell Oncol (Dordr); 2020 Apr; 43(2):195-209. PubMed ID: 31848929
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers.
Khoshghamat N; Jafari N; Moetamani-Ahmadi M; Khalili-Tanha G; Khajavi Rad MH; Sahebdel S; Khalili-Tanha N; Soleimanpour S; Khazaei M; Hassanian SM; Ferns GA; Avan A
Pathol Res Pract; 2021 Apr; 220():153390. PubMed ID: 33640713
[TBL] [Abstract][Full Text] [Related]
7. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
[TBL] [Abstract][Full Text] [Related]
8. [Current status and prognosis of immune checkpoint inhibitors for esophageal cancer].
Gao HJ; Shang XB; Yu ZT
Zhonghua Wai Ke Za Zhi; 2019 Oct; 57(10):77-82. PubMed ID: 31510736
[TBL] [Abstract][Full Text] [Related]
9. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
12. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
13. [History and Perspective of Chemotherapy in Advanced Esophageal Cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract][Full Text] [Related]
14. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
15. Immuno-oncology for esophageal cancer.
Yamamoto S; Kato K
Future Oncol; 2020 Nov; 16(32):2673-2681. PubMed ID: 32777942
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab as a first-line therapy in spinocellular esophageal cancer.
Křížová L; Charvát F; Petruželka L
Klin Onkol; 2021; 34(1):59-61. PubMed ID: 33657821
[TBL] [Abstract][Full Text] [Related]
17. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.
Huang J; Xu B; Mo H; Zhang W; Chen X; Wu D; Qu D; Wang X; Lan B; Yang B; Wang P; Zhang H; Yang Q; Jiao Y
Clin Cancer Res; 2018 Mar; 24(6):1296-1304. PubMed ID: 29358502
[No Abstract] [Full Text] [Related]
18. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
19. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
[TBL] [Abstract][Full Text] [Related]
20. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
